Streetbeat News

Equity Actions

MOGU

MOGU Inc. has announced an $8M share buyback program, signaling confidence in the company's future prospects and potentially supporting the stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 1:06 pm

CERS

ETST

NANX

ZOM

Insiders are buying shares in Zomedica, Earth Science Tech, Nanophase Technologies, and Cerus, indicating potential confidence in these companies. Notable transactions include purchases by directors and CEOs at prices below $3, with Zomedica's CEO acquiring 100,000 shares. Earth Science Tech announced a stock repurchase program, Nanophase Technologies reported Q1 financial results, Cerus reported increased product revenue, and Zomedica reported a decrease in GAAP EPS and worse-than-expected sales.

Portfolio Pulse from Avi Kapoor

May 14, 2024 | 1:01 pm

CRH

Analysts have mixed views on CRH, with recent evaluations showing a shift towards a more bullish stance. The average 12-month price target for CRH has been raised to $99.71, reflecting an 11.61% increase from the previous target. Analyst actions include upgrades and new ratings, with price targets ranging from $82.00 to $110.00. CRH's financials indicate a positive revenue trend but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 1:01 pm

JAMF

Jamf (NASDAQ:JAMF) announced the pricing of a secondary offering of 8,956,522 shares at $18.25/share by Vista Equity Partners, with an option for underwriters to buy an additional 1,043,478 shares. Jamf will not sell any shares or receive proceeds but will bear costs excluding underwriting fees. Additionally, Jamf plans to repurchase 2M shares concurrent with the offering, funded by existing cash, contingent on the offering's completion.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:56 pm

AMC

GME

HOOD

Jim Cramer predicts AMC and GameStop may issue shares to capitalize on the new meme stock frenzy, highlighting their financial struggles and the opportunity to improve balance sheets. He also mentions Robinhood's role in facilitating 24-hour trading, contributing to the frenzy.

Portfolio Pulse from Shanthi Rexaline

May 14, 2024 | 12:40 pm

CTNT

Cheetah Net Supply Chain Service has priced its share offering at $0.62 per share, with a total of 13.21 million shares being offered.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:38 pm

APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has refinanced its existing debt with a new up to $475 million non-dilutive credit facility provided by Sixth Street. The company received $375 million at close and has the option to access an additional $100 million. The majority of the initial proceeds were used to buy out the existing SFJ Pharmaceuticals development liability, significantly improving Apellis' liquidity by eliminating $366 million in SFJ payments through 2027.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:30 pm

FTXN

IEO

MPC

Marathon Petroleum Corporation (NYSE:MPC) announced significant management changes, appointing Maryann T. Mannen as CEO, effective August 1, 2024. Mannen, with a 38-year tenure in the energy sector, succeeds Michael J. Hennigan, who will become Executive Chairman. The company also reported a sharp decline in adjusted EBITDA for the first quarter of FY24, despite exceeding revenue consensus. MPC shares fell by 0.95% following the announcement. Investors can also gain exposure to MPC through IShares U.S. Oil & Gas Exploration & Production ETF (NYSE:IEO) and First Trust Nasdaq Oil & Gas ETF (NASDAQ:FTXN).

Portfolio Pulse from Lekha Gupta

May 14, 2024 | 12:25 pm

AGS

Emmett Investment Management, owning about 1.5% of PlayAGS, Inc. (AGS), opposes its proposed take-private deal with Brightstar Capital Partners, claiming it undervalues the company. Emmett intends to vote against the transaction, as detailed in an open letter to AGS stockholders.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:16 pm

ESPR

Esperion has been granted a five-year patent extension for Bempedoic Acid, a key drug in its portfolio. This extension enhances the drug's commercial lifespan and potentially its profitability.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:16 pm